Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations

  • Authors:
    • Andrzej Semczuk
    • Anna Lorenc
    • Lechoslaw Putowski
    • Konrad Futyma
    • Jaroslaw Bryk
    • Pawel Miotla
    • Ewa Bartnik
  • View Affiliations

  • Published online on: November 1, 2006     https://doi.org/10.3892/or.16.5.1041
  • Pages: 1041-1045
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Somatic mitochondrial DNA (mtDNA) mutations have been found in a subset of endometrial cancers (EC) from different populations. We have investigated the relationship between mtDNA changes and clinical and pathological variables of women affected by EC. mtDNA mutations were detected both in early (3/32; 9%) and in advanced (1/8; 12%) stages of uterine tumors. However, patients carrying the mtDNA mutations or the normal mtDNA sequence had indistinguishable clinicopathological data, including age, clinical stage, histological grade and type or depth of myometrial invasion. It is noteworthy that mtDNA mutations were not detected in hyperplastic endometrial tissues or in ECs coexisting with hyperplasia, nor in a single case of endometrial stromal sarcoma. LOH at the tumor suppressor genes RB1 and TP53 as well as p16INK4A alterations (LOH, gene deletion) were found in tumors carrying mtDNA mutations. These results suggest that somatic mtDNA mutations are detected in a subset of ECs, although they are unrelated to clinicopathological variables of cancer.

Related Articles

Journal Cover

November 2006
Volume 16 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Semczuk A, Lorenc A, Putowski L, Futyma K, Bryk J, Miotla P and Bartnik E: Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncol Rep 16: 1041-1045, 2006
APA
Semczuk, A., Lorenc, A., Putowski, L., Futyma, K., Bryk, J., Miotla, P., & Bartnik, E. (2006). Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncology Reports, 16, 1041-1045. https://doi.org/10.3892/or.16.5.1041
MLA
Semczuk, A., Lorenc, A., Putowski, L., Futyma, K., Bryk, J., Miotla, P., Bartnik, E."Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations". Oncology Reports 16.5 (2006): 1041-1045.
Chicago
Semczuk, A., Lorenc, A., Putowski, L., Futyma, K., Bryk, J., Miotla, P., Bartnik, E."Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations". Oncology Reports 16, no. 5 (2006): 1041-1045. https://doi.org/10.3892/or.16.5.1041